- |||||||||| Phase classification, Enrollment change: Studies of Heritable Disorders of Connective Tissue (clinicaltrials.gov) - Apr 6, 2018
P, N=929, Completed, Trial primary completion date: Dec 2058 --> Dec 2030 Phase classification: P=N/A --> P | N=1335 --> 929
- |||||||||| Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Enrollment change, Trial termination: The Effects of Aldara as an Adjunct to Laser Treatment (clinicaltrials.gov) - Mar 22, 2018 P2, N=7, Terminated, Phase classification: P=N/A --> P | N=1335 --> 929 N=20 --> 7 | Completed --> Terminated; Failure to enroll enough participants
- |||||||||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Clinical: Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA (clinicaltrials.gov) - May 31, 2017 P2/3, N=36, Completed, Suspended --> Terminated; drug company is no longer making the drug Active, not recruiting --> Completed
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, Enrollment change: Clinical Trial Using Humira in Netherton Syndrome (clinicaltrials.gov) - Jun 29, 2016 P2, N=11, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=23 --> 11
- |||||||||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Clinical: Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA (clinicaltrials.gov) - Jan 25, 2016 P2/3, N=33, Active, not recruiting, Active, not recruiting --> Completed | Trial primary completion date: Oct 2015 --> Jul 2015 Trial primary completion date: Dec 2015 --> Mar 2015
- |||||||||| recombinant ectodysplasin A1 (APO200) / Valerio Therap, Pierre Fabre
Trial completion, IO biomarker: Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) (clinicaltrials.gov) - Jan 20, 2016 P2, N=6, Completed, Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: Clinical Trial Using Humira in Netherton Syndrome (clinicaltrials.gov) - Nov 16, 2015 P2, N=23, Recruiting, Active, not recruiting --> Completed Trial primary completion date: Jun 2016 --> Dec 2016
- |||||||||| recombinant ectodysplasin A1 (APO200) / Valerio Therap, Pierre Fabre
Enrollment closed, IO biomarker: Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) (clinicaltrials.gov) - Sep 8, 2015 P2, N=6, Active, not recruiting, N=28 --> 269 | Trial primary completion date: Dec 2013 --> Feb 2013 Recruiting --> Active, not recruiting
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: Clinical Trial Using Humira in Netherton Syndrome (clinicaltrials.gov) - Jun 11, 2015 P2, N=23, Recruiting, Recruiting --> Completed Trial primary completion date: Jan 2016 --> Jun 2016
- |||||||||| Enrollment closed, Trial primary completion date: Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC) (clinicaltrials.gov) - Jun 9, 2015
P1/2, N=15, Active, not recruiting, Trial primary completion date: Jan 2016 --> Jun 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Oct 2015
- |||||||||| linsitinib (ASP7487) / VasaraGen
Enrollment change, Trial primary completion date, Stroma: Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors (clinicaltrials.gov) - Apr 17, 2015 P2, N=40, Active, not recruiting, Trial primary completion date: Jan 2015 --> May 2015 N=20 --> 40 | Trial primary completion date: Dec 2013 --> Dec 2016
- |||||||||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Clinical: Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA (clinicaltrials.gov) - Mar 11, 2015 P2/3, N=34, Active, not recruiting, Recruiting --> Completed | Trial primary completion date: Oct 2011 --> Apr 2015 Recruiting --> Active, not recruiting
- |||||||||| Trial completion, Trial primary completion date: Treatment of Nevus Flammeus With Alexandrite Laser (clinicaltrials.gov) - Feb 24, 2015
P=N/A, N=19, Completed, N=18 --> 3 | Recruiting --> Terminated Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Dec 2014
- |||||||||| Trial completion, Enrollment change: Port Wine Stains Treatment Matrix RF Study (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=10, Completed, Recruiting --> Completed | N=20 --> 7 | Trial primary completion date: Mar 2014 --> Oct 2014 Recruiting --> Completed | N=20 --> 10
- |||||||||| lenalidomide / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: LENAKAP: Lenalidomide in Kaposi Disease Associated With HIV Infection (clinicaltrials.gov) - Aug 1, 2014 P2, N=12, Terminated, N=20 --> 5 | Recruiting --> Terminated | Trial primary completion date: Nov 2013 --> May 2014; Study was terminated due to under enrollment N=35 --> 12 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2013 --> Feb 2014
|